New HIV prevention shot trial targets drug injectors

NCT ID NCT07199335

Recruiting now Prevention Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a long-acting injectable HIV prevention drug, called cabotegravir, can work for people who inject drugs. The trial will enroll 100 adults who have injected non-prescription drugs in the past 6 months and are at risk for HIV through sexual contact. Participants will receive the injection along with support services, and researchers will track how many stick with the treatment for 7 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cabotegravir (long-acting injectable)
What this could lead to: If successful, this could provide a practical HIV prevention option for people who inject drugs, reducing infection rates in a high-risk group.
What could go wrong: This is a small, early-phase study (100 participants) focused on feasibility, not proof of effectiveness. Participants may not stick with the injections, and results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INJECTION DRUG USE SUBSTANCE USE DISORDER (SUD)

Contacts and locations

Locations

Fenway Health
RECRUITING

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.